Skip to main content

Table 2 Demographic data of the patients with partial response and failure to sodium channel blocking antiseizure medications

From: Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients

  All (n = 91) Partial response (n = 23) Failure (n = 68) p
Onset age (year) 12.8 (4.5–20.0) 11.0 (3.0–19.5) 13 (6.0–20.0) 0.496
Male 46 (50.5) 11 (47.8) 35 (51.5) reference
Female 45 (49.5) 12 (52.2) 33 (48.5) 0.476
Seizure type
 Focal 59 (64.8) 14 (60.9) 45 (66.2) 0.811
 Generalized 27 (29.7) 8 (34.8) 19 (27.9)  
 Unspecified 5 (5.5) 1 (4.3) 4 (5.9)  
Etiology
 Structural 21 (23.1) 5 (21.7) 16 (23.5) 0.659
 CNS infection 6 (6.6) 2 (8.7) 4 (5.9)  
 Genetic 3 (3.3) 0 (0.0) 3 (4.4)  
 Autoimmune 3 (3.3) 0 0.0) 3 (4.4)  
 Unknown 58 (63.7) 16 (69.6) 42 (61.8)  
Number of ASMs
 1 7 (7.7) 1 (4.3) 6 (8.8)  
 2 24 (26.4) 6 (26.1) 18 (26.5)  
 3 35 (38.5) 10 (43.5) 25 (36.8)  
 4 14 (15.4) 5 (21.7) 9 (13.2)  
 5 9 (9.9) 1 (4.3) 8 (11.8)  
 6 2 (2.2) 0 (0.0) 2 (2.9)  
Concurrent ASMs
 Carbamazepine 23 5 18  
 Clobazam 9 1 8  
 Gabapentin 2 0 2  
 Lacosamide 3 1 2  
 Lamotrigine 35 9 26  
 Levetiracetam 54 13 41  
 Oxcarbazepine 15 7 8  
 Perampanel 11 1 10  
 Phenobarbital 12 2 10  
 Phenytoin 18 4 14  
 Pregabalin 3 0 3  
 Topiramate 28 11 17  
 Valproic acid 32 8 24  
 Vigabatrin 4 1 3  
 Zonisamide 24 5 19  
  1. Continuous variables were presented as median (interquartile range)
  2. Categorical variables were presented as n (%)
  3. Abbreviations: CNS central nervous system, ASM antiseizure medication